EGFR/HER2-IN-17

EGFR/HER2-IN-17 (Compound 7h) is a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) . EGFR/HER2-IN-17 inhibits cancer cell proliferation. EGFR/HER2-IN-17 interacts with the binding pockets of EGFR and HER2, activating caspase-3 and caspase-8, and decreases the expression of Bcl-2, thereby inducing apoptosis. EGFR/HER2-IN-17 is promising for research of cancers[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Bcl-2 Family; Caspase; EGFR

Related Pathways

Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

COC1=CC(NC(COC2=CC=C(C3=NN(C(C)=O)C(C4=CC=C(C)C=C4)C3)C=C2)=O)=CC(OC)=C1OC

Molecular Formula

C29H31N3O6

Molecular Weight

517.57

References & Citations

[1]Al-Wahaibi L H, et al. Design, Synthesis, and Computational Studies of Novel Pyrazoline-Based Dual EGFR/HER2 Inhibitors with Apoptotic Antiproliferative Activity[J]. Journal of Molecular Structure, 2025: 142364.